Search
lumateperone (Caplyta)
Indications:
- schizophrenia
- improves positive & negative symptoms
- FDA-approved for bipolar depression [2]
Adverse effects:
- somnolence or sedation (24% vs 10%*)
- dry mouth (6% vs 2%*)
- potential adverse reactions associated with antipsychotics
- neuroleptic malignant syndrome, tardive dyskinesia, falls, seizures, cognitive impairment, motor impairment, dysphagia, body temperature dysregulation
- orthostatic hypotension & syncope
- leukopenia, neutropenia, agranulocytosis
* vs placebo
- boxed warning:
- increased risk of death in elderly with dementia-related psychosis.
Drug interactions:
- avoid concurrent use with CYP3A4 inducers including phenobarbital, or moderate-strong CYP3A4 inhibitors such as telithromycin (Ketek)
Mechanism of action:
- function unknown,
- thought to have a triple mechanism of action that targets serotonin, dopamine, & glutamate neurotransmitter pathways
Interactions
drug adverse effects of antipsychotic agents
General
antipsychotic agent
Database Correlations
PUBCHEM correlations
References
- Hlavinka E.
FDA Approves Novel Schizophrenia Drug - Lumateperone also in
development for other neuropsychiatric disorders.
MedPage Today December 23, 2019
https://www.medpagetoday.com/psychiatry/schizophrenia/84073
- Brooks M
FDA Grants New Indication to Lumateperone (Caplyta) for Bipolar Depression.
Medscape. December 20, 2021
https://www.medscape.com/viewarticle/965134